March 4th, 2014
Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
February 11th, 2014
Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.
Cellectar’s product candidates are built on a novel, cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs). We have shown that PLEs become trapped in malignant tumor cell membranes because tumor cells cannot metabolize and eliminate them.
Cellectar is developing a portfolio of imaging and therapeutic agents that capitalize on the unique attributes of its cancer-targeting technology. Because of the variety of agents that preclinical data suggest can be effectively linked to Cellectar’s phospholipid ether (PLE) delivery and retention platform, the opportunities for development span a broad range of uses and indications.